NMR-based quality control approach for the identification of false positives and false negatives in high throughput screening

Current Drug Discovery Technologies

Volumn 3, Issue 2, 2006, Pages 115-124

  Dalvit, Claudio ^a   Caronni, Dannica ^a   Mongelli, Nicola ^a   Veronesi, Marina ^a   Vulpetti, Anna ^a  

^a NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

Enzyme inhibitors; False negatives; False positives; HTS; NMR; Promiscuous compounds

Indexed keywords

THYMIDINE PHOSPHORYLASE;

AQUEOUS SOLUTION; ARTICLE; DRUG INDUSTRY; DRUG SOLUBILITY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FILTRATION; HIGH THROUGHPUT SCREENING; IC 50; MOLECULE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; QUALITY CONTROL;

ALGORITHMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; ISOQUINOLINES; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUALITY CONTROL; QUERCETIN; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TECHNOLOGY, PHARMACEUTICAL; THYMIDINE PHOSPHORYLASE;

EID: 33747827255     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016306778108875     Document Type: Article

References (55)

1. Dove A.: Drug screening-beyond the bottleneck. Nature Biotechnology, 17, 859, (1999).
2. Lenz G. R., Nash H. M., Jindal S.: Chemical ligands, genomics and drug discovery. Drug Discov. Today 5, 145, (2000).
3. Kniaz D.: Drug discovery adopts factory model. Mod. Drug Disc. , 3(5), 67, (2000).
4. Ausman D.J.: Screening's age of insecurity. Mod. Drug Disc. 4(5), 33, (2001).
5. Smith A.: Screening for drug discovery: The leading question. Nature, 418, 453, (2002).
6. Eggeling C., Brand L., Ullmann D., Jäger, S.: Highly sensitive fluorescence detection technology currently available for HTS Drug Discov. Today, 8, 632 (2003).
7. Entzeroth M.: Emerging trends in high-throughput screening. Curr. Opin. Pharmacol., 3, 522, (2003).
8. Hajduk P.J. and Burns D.J.: Integration of NMR and high-throughput screening. Comb. Chem. HTS, 5, 613, (2002).
9. Jahnke W. and Widmer H.: Protein NMR in biomedical research. Cell. Mol. Life Sci., 61, 580, (2004).
10. Rishton G. M.: Reactive compounds and in vitro false positives in HTS. Drug Discov. Today, 2, 382, (1997).
11. Rishton G. M.: Nonleadlikeness and leadlikeness in biochemical screening Drug Discov. Today, 8, 86, (2003).
12. Epps D. E., Taylor B. M.: A competitive fluorescence assay to measure the reactivity of compounds. Anal. Biochem., 295, 101, (2001).
13. Huth J. R., Mendoza R., Olejniczak E. T., Johnson R. T., Cothron D.A., Liu Y., Lerner C. G., Chen J., et al.: ALARM NMR: A rapid and robust experimental method to detect reactive false positives in biochemical screens. J. Am. Chem. Soc., 127, 217, (2005).
14. Copeland R. A.: Evaluation of enzyme inhibitors in drug discovery John Wiley & Sons, Inc., Hoboken, New Jersey, USA (2005).
15. McGovern S. L., Caselli E., Grigorieff N., Shoichet B. K.: A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem., 45, 1712, (2002).
16. Roche O., Schneider P., Zuegge J., Guba W., Kansy M., Alanine A., Bleicher K., Danel F., et al.: Development of a Virtual Screening Method for Identification of "Frequent Hitters" in Compound Libraries. J. Med. Chem., 45, 137, (2002).
17. McGovern S. L., Helfand B. T., Feng B., Shoichet B. K.: A Specific Mechanism of Nonspecific Inhibition. J. Med. Chem., 46, 4265, (2003).
18. Seidler J., McGovern S. L., Doman T. N., Shoichet B. K.: Identification and prediction of promiscuous aggregating inhibitors among known drugs, J. Med. Chem., 46, 4477 (2003).
19. Ryan A. J., Gray N. M., Lowe P. N., Chung C.-w.: Effect of detergent on "promiscuous" inhibitors J. Med. Chem., 46, 3448, (2003).
20. Wu-Wong J. R., Dixon D. B., Chiou W. J., Opgenorth T. J.: Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristics. The Journal of Pharmacology and Experimental Therapeutics, 281, 791, (1997).
21. Dalvit C., Ardini E., Flocco M., Fogliatto G.P., Mongelli N., Veronesi M.: A general NMR method for rapid, efficient and reliable biochemical screening. J. Am. Chem. Soc., 125, 14620, (2003).
22. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W.: Discovering high-affinity ligands for proteins: SAR by NMR. Science, 274, 1531, (1996).
23. Hajduk P. J., Sheppard D. G., Nettesheim D. G., Olejniczak E. T., Shuker S. B., Meadows R. P., Steinman D. H., Carrera G. M. Jr., et al.: Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR J. Am. Chem. Soc., 119, 5818, (1997).
24. Moore J.M.: NMR techniques for characterization of ligand binding: utility for lead generation and optimisation in drug discovery Biopolymers (Peptide Science) 51, 221, (1999).
25. Lepre C.A., Moore J.M., Peng J.W.: Theory and Applications of NMR-Based Screening in Pharmaceutical Research Chem. Rev., 104, 3641, (2004).
26. Hajduk P. J., Meadows R. P., Fesik S.W.: NMR-based screening in drug discovery. Quarterly Reviews of Biophysics, 32, 211, (1999).
27. Peng J.W., Lepre C.A., Fejzo J., Abdul-Manan N., Moore J.M.: Nuclear magnetic resonance-based approaches for lead generation in drug discovery. Methods in Enzymology, 338, 202, (2001).
28. Peng J.W., Moore J., Abdul-Manan N.: NMR experiments for lead generation in drug discovery Prog. NMR Spectrosc., 44, 225, (2004).
29. Diercks T., Coles M., Kessler H.: Applications of NMR in drug discovery. Curr. Opin. Chem. Biol., 5, 285, (2001).
30. Coles M., Heller M., Kessler H.: NMR-based screening technologies. Drug Discov. Today, 8, 803, (2003).
31. Pellecchia M., Sem D.S., Wüthrich K.: NMR in drug discovery Nature Reviews Drug Discov., 1, 211, (2002).
32. Pellecchia M., Becattini B., Crowell K.J., Fattorusso R., Forino, M., Fragai, M., Jung, D., Mustelin, T., et al.: NMR in the hit identification and optimization process Expert Opin. Ther. Targets, 8, 597, (2004).
33. Van Dongen M., Weigelt J., Uppenberg J., Schultz J. Wikström M.: Structure-based screening and design in drug discovery. Drug Discov. Today, 7, 471, (2002).
34. Wyss D.F., McCoy M.A., Senior M.M.: NMR-based approaches for lead discovery Curr. Opin. Drug Discov. Develop., 5, 630, (2002).
35. Stockman B. J., Dalvit C.: NMR screening techniques in drug discovery and drug design. Prog. NMR Spectrosc., 41, 187, (2002).
36. Meyer B., Peters T.: NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors Angew. Chem. Int. Ed., 42, 864, (2003).
37. Zartler E.R., Yan J., Mo H., Kline A. D., Shapiro M. J.: 1D NMR methods in ligand-receptor interactions. Curr. Topics in Med. Chem., 3, 25, (2003).
38. Salvatella X., Giralt E.: NMR-based methods and strategies for drug discovery Chem. Soc. Rev., 32, 365, (2003).
39. Fernandez C., Jahnke W.: New approaches for NMR screening in drug discovery Drug Disc. Today: Technologies, 1, 277, (2004).
40. Ludwiczek M.L., Baminger B., Konrat R.: NMR Probing of Protein-Protein Interactions Using Reporter Ligands and Affinity Tags J. Am. Chem. Soc., 126, 1636, (2004).
41. Schade M., Oschkinat H.: NMR Fragment Screening: Tackling Protein-Protein Interaction Targets Curr. Opin. in Drug Disc. Develop., 8, 365, (2005).
42. Dalvit C., Flocco M., Veronesi M., Stockman B.J.: Fluorine-NMR competition binding experiments for high-throughput screening of large compound mixtures. Comb. Chem. HTS, 5, 605, (2002).
43. Dalvit C., Fagerness P. E., Hadden D.T.A., Sarver R.W., Stockman, B.J.: Fluorine-NMR experiments for high-throughput screening: theoretical aspects, practical considerations and range of applicability, J. Am. Chem. Soc., 125, 7696, (2003).
44. Dalvit C., Ardini E., Fogliatto G.P., Mongelli N., Veronesi M.: Reliable High-Throughput Functional Screening with 3-FABS. Drug Discov. Today, 9, 595, (2004).
45. Kovacs H., Moskau D., Spraul M.: Cryogenically cooled probes - a leap in NMR technology Prog. NMR Spectrosc., 46, 131, (2005).
46. 19F NMR-based screening experiments: Theoretical considerations and experimental applications. J. Am. Chem. Soc., 127, 13380, (2005).
47. 50 Measurements Performed at Unprecedentedly Low Enzyme Concentration. Drug Dev. Res., 64, 105, (2005).
48. Akoka S., Barantin L., Trierweiler M.: Concentration Measurement by Proton NMR Using the ERETIC Method. Anal. Chem., 71, 2554, (1999).
49. Dalvit C., Pevarello P., Tatò M., Veronesi M., Vulpetti A., Sundström, M.: Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water. J. Biomol. NMR, 18, 65, (2000).
50. Dalvit C., Fogliatto G.P., Stewart A., Veronesi M., Stockman B.: WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability J. Biomol. NMR, 21, 349, (2001).
51. Ernst R.R., Bodenhausen G., Wokaun A.: Principles of Nuclear Magentic Resonance in One and Two Dimensions, Clarendon Press, Oxford, (1987).
52. Focher F., Spadari S.: Thymidine Phosphorylase: A Two-Face Janus in Anticancer Chemotherapy Current Cancer Drug Targets, 1, 141, (2001).
53. Matter W. F., Brown R.F., Vlahos C.J.: The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem. Biophys. Res. Commun., 186, 624, (1992).
54. Mestres J., Veeneman G.H.: Identification of "latent hits" in compound screening collections. J. Med. Chem., 46, 3441, (2003).
55. Hwang T.-L., Shaka A.J.: Water suppression that works. Excitation sculpting using arbitrary waveforms and pulsed field gradients. J. Magn. Reson. A, 112, 275, (1995).